HSK31858 + placebo
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Non-cystic Fibrosis Bronchiectasis (NCFBE)
Conditions
Non-cystic Fibrosis Bronchiectasis (NCFBE)
Trial Timeline
Dec 6, 2022 → Jun 7, 2024
NCT ID
NCT05601778About HSK31858 + placebo
HSK31858 + placebo is a phase 2 stage product being developed by Haisco Pharmaceutical Group for Non-cystic Fibrosis Bronchiectasis (NCFBE). The current trial status is completed. This product is registered under clinical trial identifier NCT05601778. Target conditions include Non-cystic Fibrosis Bronchiectasis (NCFBE).
What happened to similar drugs?
0 of 3 similar drugs in Non-cystic Fibrosis Bronchiectasis (NCFBE) were approved
Approved (0) Terminated (1) Active (2)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06820749 | Phase 2 | Recruiting |
| NCT06637254 | Phase 2 | Recruiting |
| NCT05601778 | Phase 2 | Completed |
Competing Products
8 competing products in Non-cystic Fibrosis Bronchiectasis (NCFBE)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Benralizumab + Placebo to Benralizumab | AstraZeneca | Phase 3 | 32 |
| TIP + TIP and placebo + Placebo | Novartis | Phase 2 | 35 |
| CSL787 + Placebo | CSL | Phase 2 | 42 |
| HSK31858, tablet + Placebo | Haisco Pharmaceutical Group | Phase 3 | 47 |
| Brensocatib 10 mg + Brensocatib 25 mg + Placebo | Insmed | Phase 2 | 32 |
| Brensocatib | Insmed | Pre-clinical | 23 |
| Brensocatib 10 mg + Brensocatib 25 mg + Placebo | Insmed | Phase 3 | 37 |
| AP-PA02 | Armata Pharmaceuticals | Phase 2 | 25 |